Enlivex Ltd. filed a Form 6-K on October 28, 2026, reporting that 135 patients out of a total planned 182 have been randomized and administered the first injection of Allocetra in the company's Phase 2b clinical trial for moderate-to-severe age-related symptomatic primary knee osteoarthritis.

Key Highlights

  • Enrollment progress: 135 patients have been randomized and received the first injection of Allocetra as of October 28, 2026.
  • Trial target: The total planned enrollment for the Phase 2b study is 182 patients.
  • Indication: The trial targets patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis.
  • Treatment: The investigational product is Allocetra, administered by injection.
  • Trial phase: The study is a Phase 2b clinical trial, according to the filing.
  • Exchange and ticker: Enlivex Ltd. trades on NASDAQ:ENLV, as stated in the filing record (Commission file number 001-36578).

Enlivex Phase 2b Allocetra Trial Enrollment Update: October 2026

According to the Form 6-K filed by Enlivex Ltd. (NASDAQ:ENLV) for the month of October 2026, the Israel-based company issued a press release on October 28, 2026, disclosing the current enrollment status of its ongoing Phase 2b clinical trial. The filing states that 135 patients, out of a total planned 182, have been randomized and were administered the first injection of Allocetra in the study.

The trial is evaluating Allocetra for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis, as described in the filing. Enlivex is incorporated under the laws of the State of Israel and maintains its principal executive offices at 14 Einstein Street, Nes Ziona, Israel 7403618. The Form 6-K was signed by Chief Executive Officer Oren Hershkovitz on October 28, 2026.

The press release announcing the enrollment milestone was furnished as Exhibit 99.1 and incorporated by reference into the filing. The company files annual reports under cover of Form 20-F, as indicated on the filing's cover page. No financial results or forward-looking guidance were included in the body of this 6-K beyond the enrollment figures described above.

What Was Disclosed

Enlivex Ltd. disclosed via Form 6-K that 135 of a planned 182 patients have been randomized and received the first injection of Allocetra in the company's Phase 2b knee osteoarthritis clinical trial, as of October 28, 2026.